Oric Pharmaceuticals Inc. (ORIC): Price and Financial Metrics
ORIC Price/Volume Stats
| Current price | $9.51 | 52-week high | $16.65 |
| Prev. close | $9.76 | 52-week low | $4.89 |
| Day low | $9.35 | Volume | 589,700 |
| Day high | $10.03 | Avg. volume | 554,943 |
| 50-day MA | $12.51 | Dividend yield | N/A |
| 200-day MA | $9.18 | Market Cap | 640.75M |
ORIC Stock Price Chart Interactive Chart >
Oric Pharmaceuticals Inc. (ORIC) Company Bio
Oric Pharmaceuticals, Inc. is a clinical stage company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.
Latest ORIC News From Around the Web
Below are the latest news stories about ORIC PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ORIC as an investment opportunity.
Initial Phase 1 Dose Escalation Data for ORIC-533 in Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity and Strong Safety Profile Supporting Potential for Combination DevelopmentPreliminary evidence of clinical antimyeloma activity, including reduction in paraprotein, demonstrated in multiple patients Clean safety profile with only Grade 1 and 2 treatment related adverse events and no dose limiting toxicities or dose reductions Clinical activity, safety profile, and dose-dependent increases in immune cell activation support potential for combination studies with other multiple myeloma agents, including BCMA- and CD38-directed therapies Company to pursue strategic partne |
3 Stocks at the Forefront of Personalized Medicine TrendUnveiling the impact of personalized medicine stocks, transforming patient care, and propelling market growth seamlessly |
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 01, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on December 1, 2023 (the “Grant Date”), ORIC granted a total of 23,080 non-qualified stock options and 3,840 restricted stock units to three new non-executive employees who began their employment with ORIC in November 2023. These inducement g |
ORIC Pharmaceuticals to Participate in Upcoming Investor ConferencesSOUTH SAN FRANCISCO and SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in November: Jefferies London Healthcare Conference – Participating in a fireside chat on Thursday, November 16, 2023, at 10:00 a.m. GMT6th Annual Evercore ISI HealthCONx Conference – |
ORIC Pharmaceuticals Inc (ORIC) Reports Q3 2023 Financial Results and Operational UpdatesORIC's Cash and Investments Reach $256.2 Million, R&D Expenses Increase to $22.4 Million |
ORIC Price Returns
| 1-mo | -33.59% |
| 3-mo | -5.09% |
| 6-mo | 68.02% |
| 1-year | 71.35% |
| 3-year | -54.82% |
| 5-year | N/A |
| YTD | 3.37% |
| 2023 | 56.20% |
| 2022 | -59.93% |
| 2021 | -56.57% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...